A detailed history of Wells Fargo & Company transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Wells Fargo & Company holds 3,500 shares of PDSB stock, worth $11,305. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,500
Previous 10,489 66.63%
Holding current value
$11,305
Previous $41,000 75.61%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.55 - $4.02 $17,821 - $28,095
-6,989 Reduced 66.63%
3,500 $10,000
Q1 2024

May 10, 2024

BUY
$3.85 - $6.59 $12,412 - $21,246
3,224 Added 44.38%
10,489 $41,000
Q4 2023

Feb 09, 2024

BUY
$3.95 - $6.58 $5,127 - $8,540
1,298 Added 21.75%
7,265 $36,000
Q3 2023

Nov 13, 2023

SELL
$4.8 - $6.4 $54,115 - $72,153
-11,274 Reduced 65.39%
5,967 $30,000
Q2 2023

Aug 15, 2023

BUY
$5.03 - $9.9 $59,560 - $117,225
11,841 Added 219.28%
17,241 $86,000
Q1 2023

May 12, 2023

SELL
$5.68 - $11.99 $113,281 - $239,128
-19,944 Reduced 78.69%
5,400 $33,000
Q4 2022

Feb 13, 2023

SELL
$3.28 - $13.2 $1,213 - $4,884
-370 Reduced 1.44%
25,344 $334,000
Q3 2022

Nov 14, 2022

BUY
$2.97 - $5.79 $75,877 - $147,922
25,548 Added 15390.36%
25,714 $77,000
Q2 2022

Aug 12, 2022

BUY
$3.05 - $6.68 $42 - $93
14 Added 9.21%
166 $1,000
Q4 2021

Feb 14, 2022

BUY
$7.76 - $14.35 $38 - $71
5 Added 3.4%
152 $1,000
Q3 2021

Nov 15, 2021

BUY
$9.33 - $17.08 $223 - $409
24 Added 19.51%
147 $2,000
Q2 2021

Aug 16, 2021

SELL
$4.35 - $12.86 $4 - $12
-1 Reduced 0.81%
123 $2,000
Q1 2021

May 13, 2021

SELL
$2.28 - $6.81 $2 - $6
-1 Reduced 0.8%
124 $1,000
Q4 2020

Feb 09, 2021

BUY
$1.91 - $2.67 $97 - $136
51 Added 68.92%
125 $0
Q2 2020

Aug 13, 2020

SELL
$0.65 - $2.6 $0 - $2
-1 Reduced 1.33%
74 $0
Q1 2020

May 14, 2020

BUY
$0.67 - $3.04 $50 - $228
75 New
75 $0

Others Institutions Holding PDSB

About PDS Biotechnology Corp


  • Ticker PDSB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,458,700
  • Market Cap $91.9M
  • Description
  • PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...
More about PDSB
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.